A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination with either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients

Study Status

Open to Enrollment

Study Description

The purpose of this study is to determine the anti-tumor activity of the combination of apricoxib plus either docetaxel or pemtrexed, compared with placebo (an inactive drug that looks like the study drug) plus either docetaxel or pemetrexed in patient with Stage IIIB or Stage IV non-small cell lung cancer.

Disease Status and/or Stage

Stage IIIB/IV or Recurrent, Unresectable Non-Small Cell Lung Cancer


Tragara Pharmaceuticals

Key Eligibility

  • Men and women age 18 and older
  • Stage IIIB or IV non-small cell lung cancer
  • Additonal eligibility criteria discussed when you contact the study team

Principal Investigator

Bryan Schneider, MD


  • Gina Mileo
  • 212-746-5430

Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Erica Bersin
Tel: (646) 962-8232
[email protected]

Top of page